Microplastics appeared in all 48 samples in an infertility study. A clear look at the semen findings, their limits and current fertility guidance.
On November 2, 2026, Medscape reported that Emory University researchers had detected microplastics in semen samples from all 48 men in an infertility-evaluation study. The team presented its findings at the American Society for Reproductive Medicine’s 2026 Scientific Congress & Expo, held October 24 to 28 in Baltimore.
Researchers also reported links between particular plastics and selected semen measures. The key to reading the report is to separate three questions: what was detected, which measures were associated with it and what those measures mean for fertility.
According to Medscape’s account, the researchers recruited men seeking an infertility assessment at Emory Urology in Atlanta. Each participant provided one semen sample in a sterile glass cup. Participants also completed a questionnaire about demographic and lifestyle factors over the preceding three months.
The laboratory analysis looked for 12 polymers. These included polyethylene (PE), nylon 66, acrylonitrile butadiene styrene (ABS) and polyvinyl chloride (PVC). The team used pyrolysis, gas chromatography and high-resolution mass spectrometry to identify and measure the polymers.
The researchers then examined relationships between polymer concentrations and semen measures. They also considered whether reported behaviors were associated with the concentrations found in samples.
There were therefore two strands to the investigation. One concerned the relationship between plastics and semen findings. The other concerned possible connections between everyday behaviors and the plastics measured. Keeping those strands separate helps avoid treating a reported behavior as a confirmed source of an individual’s exposure.
Medscape reported that microplastics were detected in every participant’s sample. Detection rates for individual polymers ranged from 6% to 100%. That distinction matters: finding some microplastics in every sample does not mean every type of plastic appeared in every sample.
The main laboratory findings were:
These findings concern specific relationships between particular polymers and particular measurements. They should not be combined into a single claim that all plastics showed the same relationship with all semen measures.
The questionnaire findings added another layer. Men who reported e-cigarette use during the prior three months had higher seminal nylon 66 concentrations. Several reported food-storage and food-packaging behaviors were associated with higher PE concentrations.
PE is used in products such as plastic bags, bottles and food containers, according to the report. Its presence in common products helps explain why the findings attract attention. But the laboratory measurements and questionnaire results still need to be interpreted within the study’s design.
The study was observational. It did not establish whether microplastic exposure preceded the semen differences or caused them. Co-author Akanksha Mehta told Medscape that the findings support an association rather than a causal conclusion.
The small clinic-based sample also limits generalization. These participants were seeking infertility evaluation. Detecting microplastics in all their samples does not establish how common microplastics are in semen across the general population. Nor does it establish what concentrations might be found in a different group of men.
The single-sample design provides a snapshot rather than a picture of changes over time. The questionnaire adds self-reported information about recent behaviors. Those reported associations do not identify a confirmed route of exposure for each participant.
Other influences also deserve attention. Mehta pointed to sleep, diet and exercise as possible contributors to fertility concerns. The practical interpretation is not to choose plastics as the sole explanation whenever a semen result raises questions.
Comparisons with earlier studies require care too. The researchers noted that previous human semen studies varied considerably in size and analytical methods. Results obtained through different approaches should not be treated as directly interchangeable.
Finally, the study reported semen measures rather than pregnancy or live-birth outcomes. Co-author Audrey Gaskins called for larger studies focused on clinical outcomes. That distinction separates a laboratory research signal from evidence about the outcomes people planning a family ultimately care about.
The Emory findings sit within an existing line of human reproductive research. A 2026 narrative review in the International Journal of Impotence Research described studies that detected microplastics in human semen and reported associations with semen measures.
The review identified standardized exposure assessment and longitudinal human research as priorities. Following people over time would address a different question from measuring exposure and semen characteristics at one point. The review also found that human evidence has not established firm clinical risk estimates. Evidence concerning pregnancy outcomes and assisted reproductive technology remained predominantly experimental or hypothetical.
Established clinical guidance provides another important reference point. The European Association of Urology describes semen parameters as surrogate measures. In plain language, they are indirect indicators rather than a final answer about fertility. Its guidance states that semen analysis alone cannot distinguish fertile from infertile men. No individual parameter is diagnostic by itself.
That applies to concentration as well as motility and morphology. A study linking an exposure with one of these measures therefore needs to be read alongside the wider clinical picture. The association is worth investigating without turning the measurement into a verdict about an individual.
Other research presented at the same congress reinforces the value of a broad view. ASRM reported that a nationwide study of more than 29,000 men found neighborhood socioeconomic disadvantage associated with lower sperm concentration and total motile sperm count. That separate finding does not explain the microplastics results. It does show why reproductive research considers social and environmental circumstances alongside individual exposures.
EAU guidance also identifies obesity, low physical activity, smoking and high alcohol intake as factors associated with decreased sperm quality. It recommends addressing these established factors in men with infertility. The microplastics report adds a research question to that context rather than replacing it.
For someone with a current fertility concern, the useful next conversation is about a standard assessment with a qualified healthcare professional. EAU guidance describes an evaluation that includes medical and reproductive history, physical examination, semen analysis and hormonal evaluation. The emphasis is on bringing the relevant information together rather than selecting one exposure as the answer.
A useful question for that conversation is how a particular result fits the rest of the assessment. This keeps attention on the individual’s circumstances. It also leaves room to discuss environmental concerns without assuming they explain the entire situation.
Exposure reduction deserves similarly proportionate language. Mehta told Medscape it was too early to tell patients to avoid microplastics. If patients asked about the subject, she would support reducing exposure when feasible.
That is a cautious position rather than a fertility treatment recommendation. An optional choice to reduce exposure should remain separate from a claim that doing so will improve sperm measures or the chance of pregnancy. The study does not justify attaching such a promise to a change in packaging or food storage.
The questionnaire findings should not become a personal exposure checklist either. Reporting an association with food-storage habits or e-cigarette use is different from showing which change would produce a meaningful clinical benefit. For personal decisions, the relevant discussion belongs within qualified care rather than a headline-led plan.
It may also help to separate a fertility question from questions about changing sexual wellbeing or connection with a partner. Each deserves clear language and its own context. Naming the actual concern keeps a striking research finding from taking over a broader discussion about adult sexual health.
The most useful response is neither to dismiss the finding nor to treat it as a personal diagnosis. It is to identify the question that needs answering before changing a health decision.
Today, write down one question you would want a qualified healthcare professional to answer before this headline changes your decisions.
Deciding whether to bring a microplastics report into a fertility discussion is where Sexential adds educational context, not a clinical verdict. Sexential explains sexual function and aging for adults aged 35 to 65. Its calm coverage relates biology to everyday life without diagnosing readers or recommending personal treatment.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A review of new advice on sexual pleasure after 40, with context on changing preferences, mutual choice and symptoms that need medical attention.
Understand menopause-related vaginal comfort, changing desire, practical comfort options and when to seek individualized medical advice.
The Lancet’s men’s health series connects biology with gender and social conditions. Here is its relevance to sexual wellbeing and access to care.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
